Merit Financial Group LLC Has $2.19 Million Stock Holdings in Novo Nordisk A/S $NVO

Merit Financial Group LLC lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 113.1% during the fourth quarter, Holdings Channel reports. The firm owned 43,039 shares of the company’s stock after purchasing an additional 22,844 shares during the quarter. Merit Financial Group LLC’s holdings in Novo Nordisk A/S were worth $2,190,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Smith Chas P & Associates PA Cpas raised its position in Novo Nordisk A/S by 105.3% during the third quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock valued at $22,497,000 after buying an additional 207,959 shares during the period. Clifford Swan Investment Counsel LLC grew its stake in Novo Nordisk A/S by 13.7% in the third quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock valued at $17,267,000 after purchasing an additional 37,453 shares in the last quarter. Markel Group Inc. grew its stake in Novo Nordisk A/S by 4.9% in the third quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock valued at $131,436,000 after purchasing an additional 110,061 shares in the last quarter. Cantor Fitzgerald Investment Advisors L.P. bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth about $1,294,000. Finally, WCM Investment Management LLC boosted its stake in shares of Novo Nordisk A/S by 3.7% during the 3rd quarter. WCM Investment Management LLC now owns 2,732,182 shares of the company’s stock worth $151,636,000 after acquiring an additional 97,477 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Etavopivat Phase III (HIBISCUS) met both co?primary endpoints—significant reduction in vaso?occlusive crises and strong hemoglobin responses—positioning Novo to file for regulatory approval in H2 2026; this materially expands the company beyond diabetes/obesity into rare blood disorders and could add a new revenue stream. NVO’s Etavopivat Hits Key Goals in Phase III Sickle Cell Disease Study
• Positive Sentiment: Ongoing share repurchase programme (part of up to DKK 15bn authorised) supports EPS and signals management confidence — buybacks can help stabilize the share price and improve shareholder returns while pipeline progress continues. Novo Nordisk A/S – share repurchase programme
• Positive Sentiment: Partnership with OpenAI to deploy AI across the business could improve R&D productivity, commercial targeting and operating efficiency over time — a strategic, longer?term positive for margins and innovation. Novo Nordisk Announces Partnership with OpenAI
• Neutral Sentiment: Investor attention and Q1 focus remain centered on Ozempic/Wegovy sales; analysts note that upcoming results and 2026 guidance will hinge on those franchises amid pricing pressure and competition—this is a mixed catalyst that could either support or limit upside. How Will Ozempic and Wegovy Sales Aid NVO’s Upcoming Q1 Results?
• Negative Sentiment: CVS Health reportedly opted out of covering GLP?1s through Medicare, a near?term access/headline risk that hit GLP?1 stocks; reduced coverage can depress demand trajectory and increases uncertainty around pricing and reimbursement. How CVS And Amazon Chipped Away At Eli Lilly, Novo Nordisk Stocks
• Negative Sentiment: Competitive risk from potential new entrants (e.g., Pfizer pursuing a monthly weight?loss shot) could erode pricing power and market share in obesity/weight?loss markets over time, adding pressure to growth expectations. A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly’s and Novo’s GLP-1 Duopoly

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $39.45 on Wednesday. The business has a 50 day moving average price of $39.70 and a 200 day moving average price of $48.06. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $81.44. The company has a market cap of $176.16 billion, a price-to-earnings ratio of 11.37, a PEG ratio of 9.54 and a beta of 0.73. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Research analysts predict that Novo Nordisk A/S will post 3.37 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The firm also recently announced a dividend, which was paid on Wednesday, April 8th. Investors of record on Monday, March 30th were paid a dividend of $1.2751 per share. The ex-dividend date was Monday, March 30th. This represents a yield of 723.0%. Novo Nordisk A/S’s dividend payout ratio is presently 50.43%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Sanford C. Bernstein assumed coverage on Novo Nordisk A/S in a research note on Wednesday, March 18th. They set an “outperform” rating and a $175.00 price target for the company. Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, April 7th. TD Cowen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price for the company. in a research note on Tuesday, March 10th. Kepler Capital Markets downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Finally, Nordea Equity Research downgraded Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating and nineteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.